Welcome to our dedicated page for BCTXF news (Ticker: BCTXF), a resource for investors and traders seeking the latest updates and insights on BCTXF stock.
BriaCell Therapeutics Corp. (BCTXF) is a clinical-stage biotechnology company pioneering targeted immunotherapies for advanced breast cancer. This news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Key resources include: Phase trial progress for Bria-IMT immunotherapy, BriaDx diagnostic advancements, and corporate governance updates. Our curated news collection ensures timely access to verified press releases and market-moving developments.
Regular updates cover critical areas including FDA communications, research collaborations, and peer-reviewed data publications. This centralized repository eliminates the need to track multiple channels while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined monitoring of BriaCell's progress in merging immunotherapy innovation with precision diagnostics. Check back frequently for authoritative reporting on one of oncology's most promising clinical-stage biotechs.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) has announced a share consolidation plan to maintain Nasdaq listing compliance. The consolidation will be executed on a 15:1 basis, where every fifteen pre-consolidation common shares will be converted into one post-consolidation share.
The consolidation is scheduled to take effect on January 24, 2025, with trading of post-consolidation shares beginning on January 29, 2025 on both TSX and Nasdaq, subject to final exchange approvals. The company will maintain its trading symbols 'BCT' on TSX and 'BCTX' on Nasdaq, but under a new CUSIP number: 107930208.
No fractional shares will be issued, and any resulting fractional shares will be cancelled without compensation. The consolidation will proportionally adjust all convertible securities' exercise prices and share quantities. Registered shareholders will receive instructions via letter from Computershare Investor Services Inc. for exchanging their shares.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) has rescheduled its Annual General Meeting of Shareholders from January 23, 2025, to February 5, 2025, at 9:00 a.m. (ET) in Toronto. The postponement is due to Canadian postal service disruptions and to allow additional time for proxy solicitation.
The record date remains December 9, 2024. Previously cast votes remain valid unless shareholders choose to change them. The meeting will address the receipt of audited financial statements, election of directors, and appointment of auditors. Both the Board of Directors and Institutional Shareholder Services Inc. (ISS) recommend voting FOR all proposals.
Shareholders can vote online at www.investorvote.com, by phone at 1-866-732-VOTE, or through Computershare Shareholder Services. The company has provided detailed instructions for both registered and beneficial shareholders to participate in the voting process.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2021, occurring in two parts from April 10-15 and May 17-21. The company will present data on its lead immunotherapy candidate, Bria-IMT™, focused on advanced breast cancer. Key findings include clinical and pathological analyses highlighting disease control and patient survival. Additionally, BriaCell approved the granting of 617,300 stock options to insiders, exercisable at $4.24 per share, vesting immediately, with a five-year expiration.
BriaCell Therapeutics Corp. has successfully closed its underwritten public offering, raising approximately US$25 million. The offering included 4,852,353 common units priced at US$4.25 per unit, plus 1,030,000 pre-funded units at US$4.24 per unit. The funds will be used for clinical trials, research, and general corporate activities. Additionally, the underwriter exercised its over-allotment option to purchase 882,352 warrants.
Common shares and warrants began trading on Nasdaq under symbols BCTX and BCTXW on February 24, 2021.
BriaCell Therapeutics Corp. has announced a public offering of 5,882,353 units, priced at US$4.25 each, to raise approximately US$25 million before expenses. Each unit comprises one share of common stock and one warrant, with warrants priced at US$5.3125 and exercisable for five years. The offering is set to close on February 26, 2021, subject to conditions. Funds will be allocated for clinical trials, research, and general corporate purposes. The securities are approved for trading on the Nasdaq under the symbols BCTX and BCTXW, starting February 24, 2021.
